All In Biotech

Drug Trial Radar · NCT04735536

Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG

A Pilot Electroencephalography (EEG) Study to Evaluate the Effect of CT1812 Treatment on Synaptic Activity in Subjects With Mild to Moderate Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Nov 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

16

Actual

Start

Jul 9, 2020

Primary completion

Apr 26, 2023

Study completion Apr 26, 2023

Sponsor

Lead sponsor
Cognition TherapeuticsIndustry
Sponsor type
Industry
Collaborators
National Institute on Aging (NIA)
First posted
Feb 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-site, randomized, double-blind, placebo-controlled, 29-day, 2-period crossover Phase 2 study of 1 dose level of CT1812 (active) or placebo in adults with mild to moderate AD.

Conditions

  • Alzheimer Disease

Interventions

  • CT1812Drug

    Active Treatment- CT1812 at a dose of 300mg

  • PlaceboOther

    Placebo Comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of TEAEs, Related TEAEs, SAEs, and Related SAEsTime frame: Up to 126 days
  2. Change in the Brain Activity Reflected by Changes of Spectral Power in Conventional Frequency Bands Measured by the Global Relative Theta (4-8 Hz) Power Obtained Through EEG Assessment.Time frame: Day 1 through Day 29 of Period 1 and Day 1 (study day 44) and Day 29 (study day 72) of Period 2
  3. Changes in Predose CT1812 Plasma Concentrations.Time frame: Baseline through Day 84: Pre and Post- Dose on Days 1, 29 AND Pre Dose Days 8, 15, 22.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Brain Research Center

    Amsterdam, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.